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Abstract
Thyroid disorders are associated with blood glucose abnormalities. For rendering the patients euthyroid, routine screening and care
are essential. Therefore, the aim of this study was to investigate the association between continuity of care (COC) and type 2 diabetes
onset among patients with thyroid disorders.
We used the national claim data. Our study population was 4099 patients with hyperthyroidism or hypothyroidism. For calculating
COC, the Most Frequent Provider Continuity Index (MFPCI), ModifiedModified Continuity Index (MMCI), and COC Index (COCI) were
used. The dependent variable was type 2 diabetes onset. The Cox proportional hazard regression model was used.
Among 4099 patients with thyroid disorders, 25.3% experienced onset of type 2 diabetes. Thyroid patients who had MFPCI and
COCI below the median were more likely to experience onset of type 2 diabetes than who had these indices above the median
(MFPCI: hazard ratio [HR] = 1.26, 95% confidence interval [CI] = 1.09–1.46; COCI: HR = 1.22, 95% CI=1.06–1.41). Our subgroup
analysis showed that female patients and those 20 to 34 years of age showed a significant association between COC and onset of
type 2 diabetes.
Patients with thyroid disorders with low COC showed an increased risk of developing type 2 diabetes. Therefore, efforts to
enhance COC among patients with thyroid disorders needs to be encouraged.
Abbreviations: CI = confidence interval, COC= continuity of care, HR= hazard ratio, ICD= international classification of disease,
MFPCI = most frequent provider continuity index, MMCI = modified modified continuity index, T2D = type 2 diabetes.
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Thyroid dysfunction is one of the most prevalent endocrine
disorders.[1] According to the American Association of Clinical
Endocrinologists, an estimated 13 million people, representing
4.8% of the population of the United States, have undiagnosed
thyroid dysfunction.[2] The prevalence of thyroid dysfunction is
on the rise in South Korea. According to the Health Insurance
Review and Assessment Service, the number of people with
thyroid dysfunction has increased from 914,000 in 2009 toEditor: Daryle Wane.
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11,264,000 in 2016.[3] Along with this trend, comorbidities
including heart failure,[4] atrial fibrillation,[5] cardiovascular
diseases,[6] depression,[7] and metabolic disorders[8] have also
increased. Previous studies have focused on the relationship
between thyroid dysfunction and diabetes.[9–13]
Thyroid dysfunction and diabetes are the two most common
endocrine system disorders. Furthermore, these two diseases are
closely related,[9–13] as evidenced by the term “thyroid diabe-
tes.”[9–15] Previous studies have studied the relationship between
thyroid hormone and blood glucose. According to these studies,
hyperthyroidism is related to hyperglycemia as a result of
increased glucose gut absorption owing to the excess thyroid
hormones.[13] In addition, increased proinsulin levels are
observed in untreated Graves’ disease.[12] Hypothyroidism can
also be related to decreased glucose intolerance and insulin
sensitivity.[10,16] Moreover, it has been reported that hypothy-
roidism is associated with metabolic syndrome and could be
indirectly related to the diabetes onset.[17] Insulin and glucose
status may also be unstable owing to the effect of abnormal
thyroid hormone levels.[11–13] Therefore, controlling thyroid
hormones is imperative to prevent the onset of diabetes among
patients with thyroid dysfunction.
According to the previous study, appropriate timely treatment
along with routine screening programs could prevent negative
outcomes.[1] In this respect, continuity of care (COC) could be
one of the appropriate methods to control a patient’s thyroid
hormone status and monitor the onset of complications. COC
means a continuous relationship between physicians and
patients.[18] A high level of COC has been associated with
Lee et al. Medicine (2019) 98:52 Medicinepositive outcomes including better quality of care,[19] treatment
adherence,[20] and improved self-management.[21] Particularly,
this concept is important for patients with chronic disease
because it can prevent sudden aggravation of the condition.[22]
Although COC is an important concept for patients with
chronic diseases,[23] there are few studies on the outcome of COC
in patients with thyroid dysfunction. Therefore, this study aimed
to investigate the association between COC and onset of type 2
diabetes (T2D) among patients with thyroid dysfunction in South
Korea using nationwide claim data. We hypothesized that
patients with thyroid dysfunction along with low COC are more
likely to experience onset of T2D.2. Methods
2.1. Data and study population
We used the Korean National Health Insurance claims database
from 2002 to 2013, which includes the claims data of 1,025,340
individuals, accounting for 2% of the South Korean population.
The cohort population was selected using random sampling
methods. This data is secondary data and does not contain any
data which can identify individual. Therefore, ethical approval is
exempted. The requirement for informed consent was waived
because this study was based on routinely collected claims data.
Our study population included those who visited medical
institutions with thyroid disorders (International Classification of
Disease [ICD] codes E01–03, hypothyroidism, and E05,
hyperthyroidism). To calculate COC, we excluded those who
visited medical institutions fewer than four times during 2 years
from the onset of their thyroid disorder diagnosis. Additionally,
we also excluded those whose onset of thyroid disorder year was
in 2012 or 2013, in consideration of the follow-up time.
Therefore, the final study population included 4099 patients with
thyroid disorders.2.2. Variables
We used three indices for measuring COC. First, the Most
Frequent Provider Continuity Index (MFPCI) measures the
frequency of visits to the most frequent provider. Second, the
Modified Modified Continuity Index (MMCI) measures not only
the total number of visits to medical institutions but also the total
number of providers available. This index reflects the number and
distribution of visits to other providers. Third, the COC Index
(COCI) integrates both the MFPCI and MMCI. The COCI
measures an individual’s COC while considering the effect of the
total number of providers and total number of visits.
MFPCI ¼Maxðn1; n2; . . . ; nMÞ
N
;MMCI ¼
1 MNþ0:1
 
1 1Nþ0:1
  ;COC
¼
PM
i¼1 n
2
i N
NðN  1Þ ;
where N is the total number of visits, ni is the number of visits
to provider i, M is the total number of providers.
Our dependent variable is T2D onset. Patients who visited a
medical institution and were diagnosed with T2D (ICD-10 code
E11) after 2 years from the onset of a thyroid disorder were
classified into the T2D onset group. Patients with no record of
T2D were classified into the non-onset group.2We controlled for age, sex, income, insurance type, residential
area, type of thyroid disorder, Charlson Comorbidity Index,
presence of a disability, type and location of main attending
clinic, and thyroid disorder onset year. Age was classified into
four groups (20–34, 35–54, 55–64, and ≥65 years). As the data
do not contain exact income, health insurance premiums were
used to estimate income based on three categories (low; the
bottom 20% of premiums; middle; 20% to 80% of premiums,
high; the top 20% of premiums). Residential area was classified
into capital area, metropolitan area, and rural area. The type of
thyroid disorder was classified as hypothyroidism (ICD-10 codes
E01-E03) or hyperthyroidism (ICD-10 code E05). The type of
main attending clinic was classified as general hospital, hospital,
or clinic. The location of the main attending clinic was
categorized the same as the residential area.2.3. Statistical analysis
The chi-squared test and Student’s t test were used to examine the
general characteristics of the study population. To investigate the
association between COC and onset of T2D among patients with
thyroid disorders, Cox proportional hazards model was used to
calculate hazard ratios (HRs) by adjusting for control variables.
We also conducted a set of subgroup analyses stratified by age,
sex, income, and type of thyroid disorder. All statistical analyses
were conducted using SAS software (version 9.4; SAS, Cary, NC).
Statistical significance was set at P< .05.3. Results
Table 1 shows the general characteristics of the study population.
Among 4099 patients with thyroid disorders, 1036 (25.3%)
experienced an onset of T2D. The mean MFPCI, MMCI, and
COCI were 0.897±0.165, 0.940±0.105, and 0.842±0.235,
respectively. Among those whose MFPCI, MMCI, and COCI
were less than the median, 29.3% (n=250), 27.3% (n=330),
and 28.9% (n=330) experienced T2D, respectively.
Table 2 shows the association between COC indices and onset
of T2D. Thyroid patients with their MFPCI and COCI less than
the median were more likely to experience an onset of T2D
than were those with values exceeding the median (MFPCI:
HR=1.26, 95% CI=1.09–1.46; COCI: HR=1.22, 95%
CI=1.06–1.41). MMCI did not show a statistically significant
association; however, those with values below the median had a
higher HR (HR=1.14, 95% CI=1.00–1.30), the same as the
other indices.
Table 3 shows the results of a set of subgroup analyses
stratified by type of thyroid disorder, income, age group, and sex.
Both hypothyroidism (HR=1.31, P= .0160) and hyperthyroid-
ism (HR=1.23, P= .0405) showed a significant association with
the onset of T2D when the MFPCI was below the median. Only
hypothyroidism showed a statistically significant association
with onset of T2D when the COCI was below the median (HR=
1.27, P= .0284). Regarding income, the higher income group did
not show any association of COC and onset of T2D. Regarding
age group, only the 20 to 34 age group showed an association
with onset of T2D for MFPCI (HR=1.34, P= .0237), MMCI
(HR=1.30, P= .0342), and COCI (HR=1.31, P= .0330) values
below the median. Considering sex, female patients showed a
significant association with diabetes onset when their COCI was
below the median COC, whereas male patients did not show any
association.
Table 1
General characteristics of the study population.
Onset of type 2 diabetes mellitus
Total No Yes
Variables N (%) N (%) N (%) P
Most frequent provider continuity
∗
0.897 0.165 0.902 0.162 0.884 0.278 .0025
Modified, modified continuity index
∗
0.940 0.105 0.942 0.103 0.935 0.180 .0677
Continuity of care index
∗
0.842 0.235 0.848 0.231 0.824 0.048 .0038
Most frequent provider continuity .0027
Above median 3,246 79.2 2,460 75.8 786 24.2
Below median 853 20.8 603 70.7 250 29.3
Modified, modified continuity index .0593
Above median 2,890 70.5 2,184 75.6 706 24.4
Below median 1,209 29.5 879 72.7 330 27.3
Continuity of care index .0052
Above median 3,211 78.3 2,432 75.7 779 24.3
Below median 888 21.7 631 71.1 257 28.9
Age group <.0001
20–34 1,167 28.5 902 77.3 265 22.7
35–49 1,626 39.7 1,237 76.1 389 23.9
50–64 1,017 24.8 737 72.5 280 27.5
65+ 289 7.1 187 64.7 102 35.3
Sex .0150
Male 813 19.8 635 78.1 178 21.9
Female 3,286 80.2 2,428 73.9 858 26.1
Income .7916
Low 638 15.6 482 75.6 156 24.5
Middle 2,252 54.9 1,674 74.3 578 25.7
High 1,209 29.5 907 75.0 302 25.0
Insurance type .0028
Supporter 1,683 41.1 1,299 77.2 384 22.8
Dependent 2,416 58.9 1,764 73.0 652 27.0
Residential area .9573
Capital area 1,728 42.2 1,291 74.7 437 25.3
Metropolitan area 1,184 28.9 888 75.0 296 25.0
Rural area 1,187 29.0 884 74.5 303 25.5
Type of thyroid disorder .0029
Hypothyroidism 1,888 46.1 1,369 72.5 519 27.5
Hyperthyroidism 2,211 53.9 1,694 76.6 517 23.4
Charlson comorbidity index <.0001
2+ 2,359 57.6 1,654 70.1 705 29.9
1 1,119 27.3 895 80.0 224 20.0
0 621 15.2 514 82.8 107 17.2
Disability .7947
No 3,952 96.4 2,955 74.8 997 25.2
Yes 147 3.6 108 73.5 39 26.5
Main attending clinic .2151
General hospital 1,764 43.0 1,340 76.0 424 24.0
Hospital 197 4.8 141 71.6 56 28.4
Clinic 2,138 52.2 1,582 74.0 556 26.0
Location of the main attending clinic .9406
Capital area 1,772 43.2 1,328 74.9 444 25.1
Metropolitan area 1,290 31.5 964 74.7 326 25.3
Rural area 1,037 25.3 771 74.4 266 25.7
Diabetes onset year <.0001
2004 541 13.2 315 58.2 226 41.8
2005 486 11.9 292 60.1 194 39.9
2006 416 10.2 270 64.9 146 35.1
2007 504 12.3 366 72.6 138 27.4
2008 534 13.0 404 75.7 130 24.3
2009 521 12.7 424 81.4 97 18.6
2010 497 12.1 422 84.9 75 15.1
2011 600 14.6 570 95.0 30 5.0
Total 4,099 100.0 3,063 74.7 1,036 25.3
∗
Mean ± S.D.
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Table 2
Association between continuity of care indices and onset of type 2
diabetes
∗
.
Onset of type 2 diabetes mellitus
Variables HR 95% CI P
Most frequent provider continuity
Above median 1.00 –
Below median 1.26 (1.09–1.46) .0019
Modified, modified continuity index
Above median 1.00 –
Below median 1.14 (1.00–1.30) .0598
Continuity of care index
Above median 1.00 –
Below median 1.22 (1.06–1.41) .0071
∗
Adjusted for age, sex, income, insurance, residential area, type of thyroid disorder, Charlson
comorbidity index, existence of disability, type and location of main attending clinic, and thyroid
disorder onset year.
Lee et al. Medicine (2019) 98:52 Medicine4. Discussion
In this study, we aimed to examine the association between
diverse COC indices including MFPCI, MMCI, and COCI and
onset of T2D among patients with thyroid dysfunction. The
result of this study is in line with the results of previous studies
that evaluated the effect of COC on health outcomes.[24–26]While
limited studies have previously evaluated the effect of COC in
patients with thyroid dysfunction, our study showed that patients
having thyroid dysfunction with low COC were more likely to
experience onset of T2D, and this association was generally
maintained for all three indices (MFPCI, MMCI, and COCI).
Regarding subgroup analysis, this association was also observed
regardless of the type of thyroid dysfunction (hyperthyroidism or
hypothyroidism). Additionally, female patients and patients aged
20 to 34 years showed a significant association between COC and
onset of T2D.
The association between abnormal thyroid hormone levels and
diabetes has been studied for several decades, and many studies
have shown such an association.[15,27–29] A point of similarity isTable 3
Association between continuity of care indices and onset of type 2 dia
Ons
Below median MFPC
Variables HR P
Type of thyroid disorder
Hypothyroidism 1.31 .0160 1
Hyperthyroidism 1.23 .0405 1
Income
Low 1.27 .0284 1
Middle 1.19 .0849 1
High 1.35 .1358 1
Age group
20–34 1.34 .0237 1
35–49 1.23 .0985 1
50–64 1.28 .1251 1
65+ 1.45 .2200 1
Sex
Male 1.03 .8879 0
Female 1.31 .0007 1
∗
Adjusted for age, sex, income, insurance, residential area, type of thyroid disorder, Charlson comorbidity i
4that abnormal thyroid hormone levels increased the risk of
developing diabetes.[12,13] Hyperthyroidism has been related to
increase in liver gluconeogenesis, increased peripheral insulin
resistance, and it showed an association with glucose intoler-
ance.[30,31] Hypothyroidism has also been found to be associated
with decreased glucose intolerance and peripheral insulin
sensitivity,[16,32] and improved insulin sensitivity was observed
with treatment of hypothyroidism.[33] Furthermore, a previous
study reported that hypothyroidism was associated with
metabolic syndrome and could be related to diabetes onset,
indirectly.[17] Therefore, controlling thyroid hormones levels
within the normal range is imperative in patients with thyroid
dysfunction to prevent the development of diabetes.[28]
For treating hyperthyroidism, the production and secretion of
stimulant-autoantibody about the TSH receptor should be
suppressed. Thus, anti-thyroid medications that suppress the
production and secretion of thyroid hormone are used to
maintain normal thyroid function. According to the diagnosis
and treatment guideline of thyroid disorders,[34,35] 97.1% of
endocrinologists in Korea use medications (e.g., antihyperthyroid
medication) as the initial treatment. Themain reason of treatment
failure is non-adherence to medication,[36] and thus, regular
follow-up is important. The guideline recommends conducting
follow-up 4 weeks after the first intake of medication, with 4 to 8
weeks of follow-up until normal state is achieved. The response to
treatment is assessed based on free T4 and T3 or TSH levels. A
similar treatment process is followed for hypothyroidism as well.
For patients with hypothyroidism, supplement of thyroid
hormone is needed. Intake of thyroid hormone supplement is
similar to normal thyroid hormone secretion and involves similar
mechanisms, in which thyroid hormone is secreted as T4 and
converted to T3. Therefore, maintaining TSH or FT4 in the
normal range is the target of treatment. Hypothyroidism requires
follow-up 4 to 6 weeks after taking thyroid hormone, with
continuous follow-up for about 6 to 12 months. Thus, COC is
important in the follow-up period. If patients go to another
physician without their medical records, the treatment process
could be mixed up. Therefore, low COC could influence thyroidbetes stratified by type of thyroid disorder, income, age, and sex
∗
.
et of type 2 diabetes mellitus
Below median MMCI Below median COCI
HR P HR P
.19 .0787 1.27 .0284
.10 .2955 1.19 .0849
.00 .9892 1.18 .4129
.23 .0241 1.28 .0117
.01 .9636 1.16 .2859
.30 .0342 1.31 .0330
.11 .3645 1.19 .1545
.09 .5488 1.24 .1867
.12 .6749 1.35 .3127
.92 .6276 1.04 .8417
.18 .0238 1.27 .0025
ndex, existence of disability, type and location of main attending clinic, and thyroid disorder onset year.
Lee et al. Medicine (2019) 98:52 www.md-journal.comfunction. In summary, low COC makes it difficult to follow up
the change in thyroid function according to the treatment. In this
process, considering its well-known benefits, COC could
contribute to normalizing thyroid hormone levels.
COC is related to better outcomes of care owing to several
positive effects. From the perspective of physicians, they can
obtain better knowledge about their patients and detect possible
problems sooner[37,38] because they can provide treatment
continuously and do not have to check their status from the
beginning. In terms of patients, those with high COC have high
trust in their physicians, which is potentially related to their
medication or treatment compliance.[39] Furthermore, patients
with high COC have a tendency to show better self-management
behaviors based on this trust.[21]
Considering that an unstable thyroid hormone status could
impair glucose control,[27] maintaining consistent treatment is
necessary to stabilize the thyroid hormones. Maintaining stable
levels of thyroid hormones may help in avoiding unstable blood
glucose control. According to the treatment guidelines for
patients with thyroid disorders, periodic monitoring is imperative
for judging the response to treatment and controlling the dosage
of medication according to the patient’s status.[40] In addition,
monitoring a newly diagnosed patient’s status regularly until
their status becomes stable is recommended.[40] Therefore, the
concept of COC is needed. By regularly following up the thyroid
hormone status and administering proper treatment for the
patient’s condition, thyroid hormones can be well managed.
Our subgroup analysis showed that patients in the low- or
middle-income group and the young adult group as well as female
patients showed an increased risk of developing diabetes when
their COC indices were low. In the high-income group, there was
no statistically significant association. Generally, low socioeco-
nomic groups lack social networks that provide much informa-
tion about disease.[41] Therefore, visiting physicians regularly is
important to obtain knowledge about management of their
disease or other information. Young adults have a relatively low
risk of developing diabetes, and diabetes often occurs in middle-
aged or older individuals.[42] However, in this study, patients
with thyroid disorders in the 20 to 34 age group showed a higher
rate of diabetes when they had a low COCI. Therefore, COC
should be carefully considered especially in young adults.
The results of this study should be interpreted carefully owing
to several limitations. First, this study used claims data, and the
accuracy of such data has been controversial for several years
because the original purpose of these data was for claiming
instead of research. However, a study on the accuracy of these
data showed almost 70% accuracy.[43] Second, these data did not
contain information about the severity of the diabetes and
thyroid disorders. Furthermore, the level of thyroid hormone or
blood glucose cannot be investigated because the data did not
contain lab information. In addition, other factors such as
personal lifestyle behaviors such as smoking, drinking, or
physical activities, which could affect the development of
diabetes were not available. This lack of information could
generate a potential confounding bias. Third, although we
washed out the first year of the cohort study by extracting newly
diagnosed patients with thyroid dysfunction, there could be
contamination because there were no data before 2002. Fourth,
the physicians who provided medical services could not be
identified. Thus, we calculated COC based on medical
institutions. However, a strength of this study is the investigation5of the association between thyroid disorders and diabetes by
adopting the COC concept.5. Conclusion
Considering the increasing prevalence of thyroid disorders in
Korea, additional attention must be paid to the problems
resulting from thyroid disorders. Considering the relationship
between thyroid disorders and diabetes, an effort to minimize the
effect of thyroid disorders on the development of T2D is needed.
According to the results of this study, which found that patients
with thyroid disorders with lowCOC showed an increased risk of
developing T2D, efforts to enhance COC for patients with
thyroid disorders should be encouraged. Further study should be
conducted by using laboratory data, and the differences in
thyroid hormone levels according to COC levels should be
investigated.Author contributions
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